{
    "brief_title": "Inetetamab Combined With Pyrotinib Plus Oral Vinorelbine for the Treatment of HER2-positive Metastatic Breast Cancer",
    "phase": "Phase 2",
    "drugs": "['Inetetamab', 'Pyrotinib', 'Oral Vinorelbine Tartrate']",
    "drugs_list": [
        "Inetetamab",
        "Pyrotinib",
        "Oral Vinorelbine Tartrate"
    ],
    "diseases": "['Breast Cancer']",
    "diseases_list": [
        "Breast Cancer"
    ],
    "enrollment": "30.0",
    "inclusion_criteria": "inclusion criteria: \n\n Female, Aged \u2265 18 years. \n\n Metastatic breast cancer confirmed by pathology or imaging. \n\n Pathological diagnosis of HER2 positive (definition: immunohistochemical (IHC) 3+, or IHC 2+ with in situ hybridization (ISH) testing of amplification. \n\n Previously received trastuzumab treatment. \n\n At least one Measurable target lesion according to RECIST 1.1. \n\n Eastern Cooperative Oncology Group (ECOG) score 0- 2. \n\n Sufficient organ function: Neutrophil count (ANC) \u2265 1.5 \u00d7 10 ^ 9 / L, Platelet count (PLT) \u2265 100 \u00d7 10 ^ 9 / L, hemoglobin (Hb) \u226590 g/L\uff0ctotal bilirubin (TBIL) \u2264 1.5 \u00d7 upper limit of normal value (ULN), alanine aminotransferase (ALT / AST) \u2264 2.5 \u00d7 ULN (liver metastasis patients \u2264 5\u00d7ULN), serum creatinine \u2264 1.5 \u00d7 ULN or creatinine clearance rate (CCR) \u2265 60 ml/min, Left ventricular ejection fraction (LVEF) \u226550%. \n\n ",
    "exclusion_criteria": ": \n\n Allergic to the ingredients of the study drug. \n\n Symptomatic brain or meningeal metastasis. \n\n Gastrointestinal dysfunction or gastrointestinal diseases (including active ulcers). \n\n LVEF <50%; clinical manifestations of patients with obvious arrhythmia, myocardial ischemia, severe atrioventricular block, cardiac insufficiency, and severe valvular disease. \n\n Any other medical, social or psychological conditions which are inappropriate to participate in this trial. \n\n Pregnant or lactating women, women of childbearing age who refused to take effective contraceptive measures during the study period.",
    "brief_summary": "In this phase 2 single-arm clinical trial, 30 patients with HER2-positive metastatic breast cancer after progression on trastuzumab are enrolled and receive treatment of Inetetamab plus Pyrotinib plus Oral Vinorelbine. The study aimed to access the efficacy and safety of Inetetamab combined with Pyrotinib and Oral Vinorelbine in HER2-positive metastatic breast cancer patients after progression on trastuzumab.",
    "NCT_ID": "NCT05823623"
}